ONCO
Onconetix, Inc.·Healthcare
1.09
10.656%(−0.13)
Market ClosedLast Updated: — ET
52W L: $1.0152W H: $74.38
ONCO NEWS
globenewswire.com
2d ago
Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson
Vinci Enables Realbotix Robots to Recognize People, Recall Conversations, and Track Engagement; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp.
globenewswire.com
Apr 2
Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update
Realbotix Announces Expected Delivery of 19 Robots in March, April, and May 2026 as it Scales Production Capacity; Onconetix recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a subsidiary of Realbotix Corp. CINCINNATI, Ohio, April 02, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC (“Realbotix”), the target of Onconetix's previously announced pending acquisition. On April 1, 2026, Realbotix announced that it expects to deliver 19 previously ordered robots and corresponding AI implementations for months of March, April, and May of 2026.
globenewswire.com
Mar 31
Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors
Experienced Leadership Team Positioned to Execute Pending Transformative Acquisition of Realbotix LLC and Drive Long-Term Shareholder Value CINCINNATI, Ohio, March 31, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) today announced the appointment of David White as Chief Executive Officer, effective March 18, 2026, and the appointment of Sammy Dorf as a member of the Company's Board of Directors and the Audit Committee, effective March 19, 2026. Karina Fedasz, the Company's outgoing Interim Chief Executive Officer, will continue to serve as its Interim Chief Financial Officer.
feeds.benzinga.com
Mar 27
What's Going On With Onconetix Shares On Friday?
Onconetix (ONCO) shares surge 71% premarket following the Realbotix acquisition update and 1-for-5 reverse split.
globenewswire.com
Mar 25
Onconetix Highlights Realbotix's Role in Ericsson's World-First 6G Trial Demonstration
Realbotix Humanoid Robot — Ericsson's First Enterprise Robotics Client — Featured as Live Connected Endpoint in Pre-Standard 6G Over-the-Air Trial at Ericsson's U.S. Headquarters; Onconetix Has Entered into a Definitive Agreement to Acquire Realbotix
globenewswire.com
Mar 23
Onconetix, Inc. Announces 1-for-5 Reverse Stock Split
CINCINNATI, Ohio, March 23, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology, today announced that its Board of Directors (the “Board of Directors” or “Board”) has approved a 1-for-5 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on March 25, 2026.
